Clinical Study
Improved Insulin Sensitivity during Pioglitazone Treatment Is Associated with Changes in IGF-I and Cortisol Secretion in Type 2 Diabetes and Impaired Glucose Tolerance
Table 3
Interstitial measurements in adipose tissue during OGTT in 10 subjects with type 2 diabetes (T2D) and 10 subjects with impaired glucose tolerance (IGT) at baseline (week 0) and after 12 weeks of pioglitazone treatment (mean ± SEM).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*Repeated measures ANOVA over the baseline period, for example, from −30 to + 30 minutes. |